Navigation Links
YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results
Date:11/11/2010

ew product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that our JAK1/JAK2 inhibitor CYT387 and our VDA small molecule CYT997 will generate positive efficacy and safety data in future clinical trials; that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. Except as required by applicable securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Summary financial statements attached:YM BIOSCIENCES INC.
Interim Consolidated Balance Sheets
(Expressed in Canadian dollars, unless otherwise noted) September 30,  June 30, 2010 2010 (Unaudited)   Assets Current assets:   Cash and cash equivalents
$  15,095,919 $
9,460,141   Short-term deposits
25,073,158
26,184,991   Accounts receivable
,007
,184   Prepaid expenses
24,428
237,962 40,459,512
46,044,278 Property and equipment
28,855
84,775 Intangible asset
,518,7
,645,714 $
51,107,077 $
57,774,767 Liabilities and Shareholders' Equity Current liabilities:   Accounts payable
$ 693,188 $
99,277   Accrued liabilities
2,729,655
2,085,824   Deferred revenue
594,072
,523,916 4,016,915
4,309,017 Deferred revenue
2,277,27
,650,909 Shareholders' equity:   Share capital
203,522,4
'/>"/>
SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS
2. Regado Biosciences Awarded Three Grants from the Federal Government to Advance Research of Lead Programs
3. Sangamo BioSciences Awarded Grants for the Development of Four ZFP Therapeutic® Programs
4. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
5. X-BODY BioSciences Awarded Grant for Therapeutic Discovery Project Targeting Metastatic Tumor Stem Cells
6. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
7. Regado Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference in New York City
8. GeneLink BioSciences, Inc. Ranked 62nd Fastest Growing Company in North America on Deloittes 2010 Technology Fast 500™
9. Sangamo BioSciences Announces Third Quarter 2010 Conference Call and Webcast
10. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2010 Financial Results
11. Cell Biosciences to Acquire Convergent Bioscience
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... processes prefer to settle into equilibriuma state of ... the realm of non-equilibrium conditions where new possibilities ... and phases, such as temperature fluctuations, freezing and ... regulate their body temperature, airplanes to fly, and ... , But even though these conditions exist naturally ...
(Date:7/24/2014)... N.J. , July 24, 2014  CorMedix ... on developing and commercializing therapeutic products for the ... today announces receipt of notice on July 18, ... the NYSE-MKT has accepted the CorMedix plan to ... NYSE-MKT. As a result, the NYSE-MKT is continuing ...
(Date:7/24/2014)... 1000 balances – 4 steps – One Recommendation: the ... expertly narrows down the mass of product choices to ... , First, select the working environment, then enter ... and define the accuracy – it’s really that simple. ... list to models that fit best with the customer’s ...
(Date:7/24/2014)... As part of the long-term strategic approach, ... region during 2014 with potential global expansion. , "We ... DZS to manage our clinical trials globally and in ... R&D and President of SBI pharmaceuticals MENA, Dr. Riyadh ... a focus on utilizing eClinical software and flexible team ...
Breaking Biology Technology:New approach to form non-equilibrium structures 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services 2
... Oct. 23 BioWisdom Ltd (BioWisdom),the market ... industry, today announces the release of OmniViz,Visualization ... are increasingly being used in competitive business ... business decisions.,OmniViz Visualization Software can turn the ...
... Israel and JERSEY CITY, New Jersey, October 23, ... in,the development of microRNA-based diagnostics and therapeutics, today,announced ... Annual,Meeting on "Molecular Markers in Cancer". The event ... in Hollywood, Florida., The poster presentation, titled ...
... FRANCISCO, Calif., Oct. 23 Poniard,Pharmaceuticals, Inc. (Nasdaq: ... today announced that it will hold a conference ... provide a corporate update,including an update on the ... candidate., Jerry McMahon, Ph.D., chairman and chief ...
Cached Biology Technology:Rosetta Genomics to Present at the Upcoming EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer" 2Rosetta Genomics to Present at the Upcoming EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer" 3Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30 2
(Date:7/24/2014)... wildlife loss leads to conflict among people around the ... Society (WCS) Health & Ecosystems: Analysis of Linkages (HEAL) ... approach to tackle global biodiversity decline. , The harvest ... world,s people and provides protein for more than a ... no surprise that today,s unprecedented loss of wildlife, is ...
(Date:7/24/2014)... Bushmeat, the use of native animal species for food ... be a significant factor in the decline of many ... new study indicates that more than half of the ... raptors and hornbills., "By surveying not only the meat ... being eaten inside the forest by hunters and brought ...
(Date:7/24/2014)... Angeles, where electric cars ply silent freeways, solar panels ... beneath the earth, from howling winds and from the ... that it is technically and economically feasible to convert ... renewable energy. Published in Energy , the plan ... energy supply in California that could create tens of ...
Breaking Biology News(10 mins):New study draws links between wildlife loss and social conflicts 2Stanford study shows how to power California with wind, water and sun 2Stanford study shows how to power California with wind, water and sun 3Stanford study shows how to power California with wind, water and sun 4
... French . Some of the human X chromosome ... Africa, according to an international team of researchers led by ... of Montreal and the CHU Sainte-Justine Research Center. The research ... and Evolution. "This confirms recent findings suggesting ...
... July 18, 2011 Researchers at UT Southwestern Medical ... involved in the formation of colon cancer, far more ... study, published in the July 2011 Cancer Research (Priority ... cancer treatments targeting multiple genes and pathways simultaneously. Current ...
... YORK, July 16, 2011 Experts from the Center ... Center will present new research at the 2011 Alzheimer,s ... in Paris, France from July 16 21. ... impairment in retired football players, with Stella Karantzoulis, PhD, ...
Cached Biology News:Genetic research confirms that non-Africans are part Neanderthal 2NYU Langone Medical Center's tip sheet to the 2011 Alzheimer's Association International Conference 2NYU Langone Medical Center's tip sheet to the 2011 Alzheimer's Association International Conference 3NYU Langone Medical Center's tip sheet to the 2011 Alzheimer's Association International Conference 4NYU Langone Medical Center's tip sheet to the 2011 Alzheimer's Association International Conference 5NYU Langone Medical Center's tip sheet to the 2011 Alzheimer's Association International Conference 6
For removal of the zona pellucida. Sterile, Mouse Embryo tested...
... The LXQ linear ion trap mass spectrometer ... analytical laboratory., The LXQ linear ion trap ... and proteomic applications, delivering the fast cycle ... linear ion trap at an attractive price. ...
... scientists who do not have access to microarray ... their biological samples tested for the concentration of ... 1-2-3 Chose the analytes you wish ... S&S antibody menu. Send your samples to ...
... Persistent Analysis Environment 2) Dot plot, ... 3) Software Compensation 4) Cell Cycle ... Platform 7) Intelligent batch generation of graphs ... 9) Single drag-and-drop operations to perform complex ...
Biology Products: